Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment

N Engl J Med. 2024 Apr 25;390(16):1524-1526. doi: 10.1056/NEJMe2402719. Epub 2024 Apr 6.

Author

Affiliation

¹ From the Montreal Heart Institute, University of Montreal, Montreal.

PMID: 38587253
DOI: 10.1056/NEJMe2402719

No abstract available

Publication types

Editorial

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Cardiovascular Agents* / therapeutic use
Chronic Disease
Clinical Trials as Topic
Heart Disease Risk Factors
Heart Failure* / etiology
Heart Failure* / mortality
Heart Failure* / prevention & control
Humans
Myocardial Infarction* / complications
Myocardial Infarction* / drug therapy
Ramipril / therapeutic use
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
Stroke Volume
Ventricular Dysfunction, Left / drug therapy
Ventricular Dysfunction, Left / etiology

Substances

Cardiovascular Agents
sacubitril and valsartan sodium hydrate drug combination
Angiotensin Receptor Antagonists
Ramipril
Angiotensin-Converting Enzyme Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin